News >

Crawford Highlights Role of Degarelix in Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 24, 2017

E. David Crawford, MD

E. David Crawford, MD

As a GnRH antagonist available for patients with advanced prostate cancer, degarelix (Firmagon) has proven to be a solid option with its tolerable safety profile and rapid reduction in testosterone suppression, explains E. David Crawford, MD.

The 2008 FDA approval of degarelix was based off of findings from a phase III study that compared the safety and efficacy of the antagonist with leuprolide. Here, researchers evaluated the ability to maintain suppression of testosterone for up to 1 year; results showed that there were no rises in testosterone in the degarelix arm and that 96% of patients attained medical castration 3 days following the first dose.

Degarelix is currently being explored for its efficacy in patients who have prostate cancer and cardiovascular disease (NCT02663908). The ongoing phase III PRONOUNCE trial is comparing degarelix with leuprolide to see which of the 2 agents leads to a greater reduction in the risk of cardiovascular complications for patients with both conditions.

In an interview with OncLive, Crawford, a professor of radiation oncology at the University of Colorado Denver, shares insight on incorporating ADT—specifically degarelix—into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.

OncLive: When you have a patient with prostate cancer, where do therapies like degarelix fit into their treatment course?

Crawford: Degarelix is a GnRH antagonist. What Dr Andrew Schally, who received the Nobel Prize in Physiology or Medicine in 1977, was working on was trying to develop an antagonist to shut down the hypothalamic pituitary testicular axis. We never could quite get there because of molecule-delivery systems, as well as histamine release and allergic reactions. We actually settled for an agonist, which have paradoxical effects and raise testosterone before they lower it. However, the good things were that they were depots that could be 1 month, 3 months, or 6 months. Therefore, there are people who continue to pave the way to develop an antagonist [like that].

One of the first ones was cetrorelix (Cetrotide), then abarelix (Plenaxis), and now degarelix. Degarelix had solved some of the issues with the earlier ones, such as escapes and histamine release and things like that; however, it is still a 1-month depot. We sort of live in a 3-month, 4-month depot arena, but, nevertheless, when you start focusing on the attributes of degarelix compared with an agonist, what you end up seeing are some real benefits [with degarelix] that probably outweigh the monthly depot.

Degarelix gives a rapid reduction in testosterone and has some other attributes, including a lack of flares with testosterone except in between injections. There are some interesting effects on follicle-stimulating hormone (FSH) and a bunch of other things. 

What patients would be appropriate to receive degarelix?

I would use it in patients who would be candidates for ADT—almost anybody I would give it to. Particularly, I would focus on patients who had a lot of disease or flare of the disease, and could have spinal cord or urinary problems. It also gives more rapid volume reduction in the prostate. When you give radiation or an agonist, you’re actually wasting a couple of months because of the flare of testosterone. You can block it with an antiandrogen agent, but some of that still occurs.

A lot of times, the big drawback [with degarelix] is that it is 1 month. So, if I have patients at the University of Colorado Denver who are coming from Idaho or Wyoming, and they have a 4- to 6-hour drive once a month, it becomes much more problematic. We find ways around it. 

What are the adverse events, if any, associated with degarelix?

It is basically just one: injection site reaction. We know that about one-third of the patients who get their first injection and they have to get a loading dose—2 injection sites in the abdomen—will get some redness or feel some pain. It can be relatively severe in some patients. Then, after that, there are monthly maintenance doses and then that cuts down by a few percent, but not as high as the 30% [with the loading dose]. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication